Phathom Pharmaceuticals (PHAT) Income towards Parent Company (2022 - 2025)
Historic Income towards Parent Company for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' Income towards Parent Company rose 6498.03% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 1914.08%. This contributed to the annual value of -$334.3 million for FY2024, which is 6599.37% down from last year.
- Latest data reveals that Phathom Pharmaceuticals reported Income towards Parent Company of -$30.0 million as of Q3 2025, which was up 6498.03% from -$75.7 million recorded in Q2 2025.
- Over the past 5 years, Phathom Pharmaceuticals' Income towards Parent Company peaked at -$30.0 million during Q3 2025, and registered a low of -$94.3 million during Q1 2025.
- Moreover, its 4-year median value for Income towards Parent Company was -$55.0 million (2022), whereas its average is -$62.2 million.
- As far as peak fluctuations go, Phathom Pharmaceuticals' Income towards Parent Company crashed by 12319.86% in 2024, and later surged by 6498.03% in 2025.
- Phathom Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$55.0 million in 2022, then tumbled by 44.76% to -$79.6 million in 2023, then grew by 6.36% to -$74.5 million in 2024, then surged by 59.78% to -$30.0 million in 2025.
- Its Income towards Parent Company was -$30.0 million in Q3 2025, compared to -$75.7 million in Q2 2025 and -$94.3 million in Q1 2025.